Biogen Inc.’s joint venture with Samsung Electronics Co. Ltd.to develop biosimilars for the global market, including the U.S., provides the U.S. biotech with entrée into the fast-moving biosimilars space, an area CEO George Scangos has called of interest, even as his company remains intensely focused on moving forward with its rich pipeline of innovative drugs.
At the same time, it offers a clear advancement for Samsung as that company looks to break into the broader...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?